Peyronie’s disease – Knowledge and References

Peyronie's disease

Biocatalytic Nanoreactors for Medical Purposes

Published in Peter Grunwald, Pharmaceutical Biocatalysis, 2019

Oscar González-Davis, Chauhan Kanchan, Rafael Vazquez-Duhalt

Peyronie’s disease is caused by the formation of scar tissue inside the penis producing difficulties in obtaining a straight erection. Collagenase is an enzyme that selectively dissolves collagen and is used for the clinical treatment of Peyronie’s disease (Hay et al., 2013). The use of NCs has improved enzyme delivery through the dense extracellular matrices (Villegas et al., 2015).

Devices for penile traction: the long and winding road to treating Peyronie’s disease

View Article

Journal Information

Published in Expert Review of Medical Devices, 2018

Shaan A Setia, Laurence A Levine

Peyronie’s disease (PD) is characterized by the disorganized formation of fibrotic inelastic scarring within the tunica albuginea as part of an abnormal and dysregulated wound healing process. It was first reported as early as 1561 by Fallopius and Vesalius but was later described and treated in 1743 by Francois Gigot de la Peyronie (surgeon to King Louis XV) after which the disease took on his name [1]. Despite being characterized over 250 years ago, the exact pathophysiology remains unclear. The primary mechanism of injury for PD is thought to be trauma recognized or not to the penis, most commonly occurring during sexual activity. However, not all trauma leads to PD and there is likely a fine interplay between trauma and genetic predisposition [2]. PD may cause a variety of deformities and symptoms including abnormal penile curvature, narrowing, hinging, shortening, erectile dysfunction (ED), and painful erections.

Peyronie's disease

Explore chapters and articles related to this topic

Biocatalytic Nanoreactors for Medical Purposes

Devices for penile traction: the long and winding road to treating Peyronie’s disease